SEVERITY AND CLINICO-HAEMATOLOGICAL FEATURES OF APLASTIC ANEMIA IN ADULTS PRESENTING TO PUBLIC SECTOR TERTIARY CARE HOSPITAL OF LAHORE: A DESCRIPTIVE CROSS SECTIONAL STUDY
DOI:
https://doi.org/10.59058/jaimc.v20i3.68Keywords:
Aplastic anemia, pallor, severity, clinico-haematogical, cross sectional studyAbstract
Background & Objective: Aplastic anemia is a rare and heterogeneous disorder. Literature shows inconsis- tencies in frequency and its clinico-hematological findings. Objective of this study was to assess frequency of different severity grades and clinico-hematological features in newly diagnosed cases of aplastic anemia in adults.
Methods: In this descriptive, cross-sectional study, conducted in Allama Iqbal Medical College Lahore from October 2021 through April 2022, a total of 100 diagnosed cases of acquired aplastic anemia were included. Modified Camitta's criteria were applied to assess the severity of aplastic anemia. Clinical features such as pallor, fever and bleeding manifestations were determined by history and physical examination. About 3ml whole blood was collected in EDTA vial and run for complete blood count on automated hematology analyzer for hematological Parameters (Hb, Platelets, total leukocyte count and absolute Neutrophil count). Data were entered and analyzed using SPSS version 20. Quantitative variables like age, Hb, TLC and platelet count were expressed as mean ±Standard deviation. Qualitative variables such as gender, severity of aplastic anemia and clinical features were expressed as percentages.
Results: In this study, 55% participants were male and 45% were female. All patients had pallor, 61% had fever and 66% had bleeding on presentation. Regarding severity of aplastic anemia, 56% were categorized as severe, 24% as very severe and 20% were as non severe aplastic anemia.
Conclusion: Severe aplastic anemia is frequent among male population and at younger age. This information has prognostic implications. Therefore, all patients with aplastic anemia should be assessed for severity for further clinical management.
References
Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon‐Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. British Journal of hematology. 2009;147(1):43-70
Ehsan A, Shah AR, Ibrahim T. Epidemiology of acq- uired aplastic anaemia in Pakistan. The Journal of Ayub Med Collage Abbottabad. 2011;23(1):102
Das S, Tilak V, Gupta V, Singh A, Kumar M, Rai A. 24(8):549-52 Clinical, hematological, and cytogenetic profile of aplastic anemia. Egyptian Journal of Haematology. 2015;40(1):3.
Mahapatra M, Singh PK, Agarwal M, Prabhu M, Mishra P, Seth T, et al. Epidemiology, Clinico-Haema- tological Profile and Management ofAplasticAnaemia: AIIMS Experience. Journal of the Association of Phy- sicians of India. 2015 ;63(3 Suppl):30-5.
Biswajit H, Pratim PP, Kumar ST, Shilpi S, Krishna GB,AditiA.Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. North American journal of medical sciences. 2012; 4(9): 384
Taj M, Shamsi TS, Ansari SH, Farzana T, Nazi A, Nadeem M, et al. Epidemiologic and HLA Antigen Profile in Patients with Aplastic Anemia. Journal of the College of Physicians and Surgeons Pakistan. 2014;
Wali R, Fidoo Z, Adil S, Naqvi MA. Aplastic anemia: clinico-haematological features, treatment and out- come analysis. Journal of the College of Physicians and Surgeons Pakistan. 2011;21(4):219.
Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6): 726- 35
Williams DM, Lynch RE, Cartwright GE. Prognostic factors in aplastic anaemia.Clin.Haematol. 1978;7(3): 467–474.
Kwon JH, Kim I, Lee YG. Clinical course of non-severe aplastic anemia in adults. Int. J. Hematol. 2010; 91(5): 770–775.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 JAIMC
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
